Ipsen presents new analyses utilizing modern data mining approaches at ISPOR Europe 2019

Presentations showcase insights in advanced renal cell carcinoma, gastroenteropancreatic neuroendocrine tumors and acromegaly

 

Paris (France), 31 October 2019 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that results from a network meta-analysis (NMA) in advanced renal cell carcinoma (aRCC), and a UK-focused budget impact study assessing long-acting somatostatin analogues (LA-SSAs) for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP NET) will be presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2019 Annual Conference. ISPOR takes place in Copenhagen, Denmark from 2 – 6 November 2019.

 

Key studies to be presented at ISPOR Europe 2019:

  • An assessment of the budget impact of LA-SSAs in the treatment of acromegaly and GEP NET, considering attributes related to the drug delivery of LA-SSAs in the UK.
  • An NMA analyzing cabozantinib versus standard-of-care comparators in progression free survival (PFS) and overall survival (OS) in the first-line treatment of advanced renal cell carcinoma.

 

“We’re excited to be sharing two interesting sets of results – namely a comparison of first-line therapies and budget impact of a treatment approach for acromegaly and gastroenteropancreatic neuroendocrine tumors,” said Ulf Staginnus, Senior Vice President, Head Global Market Access and Pricing, Ipsen. “With more than 5,000 global healthcare leaders, seeking robust health solutions and new insights, ISPOR Europe 2019 is the perfect stage to share these results.”

 

The delivery attributes of both LA-SSAs were considered in the UK-focused study assessing the budget impact of the LA-SSAs, lanreotide versus octreotide in the treatment of acromegaly and GEP-NET. Model inputs (including drug acquisition and administration costs) were based on publicly available sources. The analysis compared the current and hypothetical market share scenarios from three perspectives in the UK: the National Health Service (NHS), a regional clinical commissioning group (CCG), and a local institution (hospital). Results suggested that increasing the use of lanreotide to a hypothetical 80% market share for lanreotide in the UK would reduce overall LA-SSAs patient treatment expenses by £2.9 million annually in the UK (a reduction of 3.6% from the current budget estimate of £80.6 million).

 

In the area of treatment provision in aRCC, Ipsen used an NMA to respond to the challenge presented to healthcare professionals by the introduction of targeted therapies in the last year with no way to objectively compare them. While randomized trials are the gold standard for comparative effectiveness research, they are not always available for clinically and economically important treatment comparisons. In this case, the NMA may offer some helpful insights as it suggests that cabozantinib significantly increases progression free survival (PFS) in intermediate and poor-risk patients when compared with standards-of-care and concludes that cabozantinib may be considered as an efficient treatment option in first-line aRCC.

 

“Modern quantitative data reviews of available agents offer additional insights into existing healthcare,” said Bartek Bednarz, Senior Vice-President, Global Product and Portfolio Strategy, Ipsen. “The network meta-analysis (NMA) for cabozantinib and budget impact model for somatostatin analogues shared at ISPOR Europe 2019 are just part of Ipsen’s ongoing commitment to demonstrating benefit for payers and improving options for patients with high unmet needs.”

 

Follow Ipsen on Twitter via @IpsenGroup and keep up to date with ISPOR Europe 2019 Conference news and updates by using the hashtag #ISPOREurope.

 

Overview of key Ipsen presentations at ISPOR Europe 2019:

Medicine Abstract title Abstract number/timing (CEST)

Cabometyx®

(cabozantinib)

 

 

Cabozantinib versus standard-of-care comparators: a network meta-analysis of progression free survival and overall survival in the first-line treatment of advanced renal cell carcinoma

PCN42; Board D5

RESEARCH POSTER SESSION 2

CANCER

Monday, November 4, 2019

Display Hours: 15:30 – 19:00

Somatuline® Autogel® (lanreotide autogel/depot) Budget impact analysis of somatostatin analogues in the treatment of GEP-NET and acromegaly in the UK

PDG23; Board J3

RESEARCH POSTER SESSION 4

DRUGS & GENERICS

Tuesday, November 5, 2019

Display Hours: 15:45 – 19:00

N/A Retrospective Gesetzliche Krankenversicherung (statutory health insurance) (GKV) research study on the initial treatment of bladder carcinoma (BCA) by transurethral bladder resection (TURB) – a comparative analysis of costs and urological follow-up therapies using standard white light- (WL-) vs. Blue light- (WL-)TURB

PCN502; Board W12

RESEARCH POSTER SESSION 2

CANCER

Monday, November 4, 2019

Display Hours: 15:30 – 19:00

 

N/A Assessing the human and economic burden of short stature: a systematic literature review

PMU142; Board V19

RESEARCH POSTER SESSION 4

MULTIPLE DISEASES

Tuesday, November 5, 2019

Display Hours: 15:45 – 19:00

ABOUT IPSEN PRODUCTS

 This press release mentions investigational uses of Ipsen products. Product indications and approvals for use vary by jurisdiction; please see SmPC/PI for full indications and safety information, including Boxed Warnings.

 

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019